Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEEPER: FOLFOXIRI plus Cetuximab vs Bevacizumab in RAS Wild-type mCRC
NCT02515734Phase 2Unknown
- Sponsor
- Japan Clinical Cancer Research Organization
- Start
- Aug 2015
- Primary completion
- Dec 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of cetuximab in colorectal cancer (CRC), sponsored by Japan Clinical Cancer Research Organization. Status: unknown.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02515734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02515734.